ProMIS Neurosciences lines up up to $175 M private placement to fund Alzheimer’s trial

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on antibody therapeutics for neurodegenerative diseases, announced that it has entered into a private investment in public equity (PIPE) financing agreement with institutional and accredited investors to raise up to approximately $175 million, the company said.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE